3M Company MMM
Verdict: Strong sell. Fair value $91.00 against a price of $165 on 12 Jan 2026, 45% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Revenue beats.
The case against: 2024 OCF ($1.82B) is significantly lower than Net Income ($4.17B) and 2023 OCF ($6.68B). This.... Total Assets dropped ~21% ($50.5B to $39.9B) and Depreciation expense fell 31%. While likely due to.... Massive swing from -$7.0B loss in 2023 (due to legal accruals) to +$4.17B profit in 2024. The....
Main risks
- Thin revenue cushion: 0.3% decline causes EBIT loss
- Revenue contraction (-11.4% 3Y CAGR) driven by Solventum spin-off and flat organic demand
- Poor Cash Flow Conversion (FCF/Net Income ~0.38x) due to ongoing legal settlement payments
- Distorted Balance Sheet with high Debt/Equity (2.95) resulting from accumulated losses/write-downs
- 2024 OCF ($1.82B) is significantly lower than Net Income ($4.17B) and 2023 OCF ($6.68B). This...
- 2024 OCF ($1.82B) is significantly lower than Net Income ($4.17B) and 2023 OCF ($6.68B). This indicates cash outflows for previously accrued legal settlements (PFAS/Combat Arms) are now draining liquidity.